RxDoctor Payments Data

Michelle Crouse, MD

Geriatric Medicine · Greenville, SCNPI 1942664610

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 20 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 6 manufacturers reported payments, led by Abbott at 37.3% of the total. Reporting peaked in 2021 at $163 and has fallen 75.7% since, to $40 in 2025.

$610in general payments, 2019–2025

Across 20 payments — averaging $30.52 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$228
  • Novo Nordisk$173
  • Pfizer$119
  • AstraZeneca$49
  • Lilly USA, LLC$27
  • Neurocrine Biosciences, Inc.$15

What the payments were for

  • Food & beverage$610100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$610 in reported general payments places this provider in the 75th percentile of 41 geriatric medicine providers in South Carolina.

See all geriatric medicine providers in South Carolina

Medicare billing

Part B allowed, 2024
$114,183
Medicare patients
499
Services billed
871

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OtezlaApremilast11$13,735
EliquisApixaban31$13,283
Trelegy ElliptaFluticasone/Umeclidin/Vilanter16$7,929
Memantine Hcl76$3,026
JardianceEmpagliflozin11$2,809
TradjentaLinagliptin11$2,700
Mirtazapine23$1,420
Losartan Potassium72$1,050
Rosuvastatin Calcium28$1,036
Donepezil Hcl73$1,022
Gabapentin40$847
Quetiapine Fumarate34$750
Divalproex Sodium17$578
Hydroxyzine Hcl14$541
Sertraline Hcl49$475

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$119$13,28331 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 41 geriatric medicine providers in South Carolina.

Other geriatric medicine in Greenville

See the full list for South Carolina

Where these figures come from

Is this you, or does something look wrong? →